CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, announced today that it obtained exclusive rights from the Massachusetts Institute of Technology for the discovery, development, and commercialization of an assay and gene therapy technologies using the SIRT1 gene, the best characterized of the recently-discovered family of sirtuin genes. This in-licensed technology, which was developed in the laboratory of Professor Leonard Guarente, (US Serial No. 11/404,146, “Sir2 Activity” and US Serial No. 10/993,903, “Method Of Extending Life Span”) will enable Sirtris to further advance its robust sirtuin platform for developing therapeutics for diseases of aging, such as diabetes.
